A novel prodrug of adriamycin in the treatment of gastric cancer peritoneal carcinomatosis

作者：Shaoping Liu, Lihua Shao, Yan-jun Zhong, Min Fang, Yang Liu, Yan Li · 发表于：Zhonghua shiyan waike zazhi · 年份：2012 · DOI：10.3760/cma.j.issn.1001-9030.2012.03.004 · 被引用次数：1 · 研究领域：Cancer, Hypoxia, and Metabolism、Cancer, Lipids, and Metabolism、14-3-3 protein interactions

Objective To study the efficacy and toxicities of the novel prodrug of adriamycin ( AcPhe-Lys-PABC-ADM,PADM) in the treatment of SGC-7901 gastric cancer peritoneal carcinomatosis animal models.Methods The homogenate of SGC-7901 gastric cancer tissue was intraperitoneally injected into BALB/C nude mice to build gastric cancer peritoneal carcinomatosis.Then animals were randomized into control ( n =9),adriamycin ( ADM ) ( n =10) and PADM ( n =10) groups and treated with normal saline (10 ml/kg),ADM (2 mg/kg) and PADM (7.2 mg/kg) every 4 days,respectively.The body weight,experimental peritoneal carcinomatosis index (ePCI),blood routine,biochemical parameters of major organs were studied to evaluate the efficacy and toxicities.Results The ePCI of PADM and ADM groups was 1.0 (1-4) and 1.5 (0-6) respectively.Compared to ePCI [6.0 (1-10) ] of control group,PADM and ADM reduced ePCI significantly (P ＜0.01 ).In terms of general status,PADM had no obvious effects on body weight (23.61 ± 0.80) g,while ADM significantly decreased body weight ( 18.40 ± 2.97 ) g ( P ＜0.01 ),compared to control group (24.32 ± 1.40) g.In addition,PADM reduced toxicities on the bone marrow,heart,liver,etc.,especially on the heart,while ADM showed obvious cardiotoxicity compared to control group.Conclusion PADM could inhibit the development of gastric cancer peritoneal carcinomatosis,with significant reduction in the liver,bone marrow and especially the heart toxicities. Key words: Gastric cancer peritone...